EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO)

Aditya K Gupta iD, Mesbah Talukder, Elizabeth A Cooper iD, Lee Magal, Avner Shemer

Pathogens · 2025

DOI: 10.3390/pathogens14101049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Hauptthemen laut MEDLINE: Onychomycosis, Voriconazole, Antifungal Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective case series evaluated off-label voriconazole for distal lateral subungual onychomycosis (DLSO) unresponsive to standard therapy. Twenty-nine culture-confirmed patients who had failed terbinafine (250 mg daily × 12 weeks) and itraconazole pulses (200 mg twice daily for 1 week/month × 3) received voriconazole (200 mg twice on day 1, then 200 mg daily for 3–4 months). Assessments occurred at 2, 4, 6–9, and 12 months; the primary endpoint was combined clinical cure (≥90% nail clearance) plus mycological cure (negative KOH and culture) at 12 months. Intention-to-treat included 29 patients; per-protocol included 27 (two did not complete follow-up). In the per-protocol cohort, combined cure was 55.6% (15/27) and mycological cure 74.1% (20/27). Complete clinical cure occurred in 66.7% (18/27); 25.9% (7/27) improved markedly, 3.7% (1/27) mildly, and 3.7% (1/27) showed no improvement. Voriconazole was well tolerated and may be considered for DLSO refractory to terbinafine ± itraconazole. Antifungal stewardship remains essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OnychomycosisVoriconazoleAntifungal AgentsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedTreatment OutcomeTerbinafineYoung Adult

Stichwörter der Autor:innen

clinical curedistal lateral subungual onychomycosis (DLSO)mycological curerefractory onychomycosisterbinafine failurevoriconazole

Substanzen

VoriconazoleAntifungal AgentsTerbinafine

Autor:innen und Institutionen

  • Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.
  • School of Pharmacy, BRAC University, Dhaka 1212, Bangladesh.
  • Department of Physiology and Pharmacology, University of Western Ontario, London, ON N6A 5C1, Canada.
  • Shemer Clinic, Netanya 4250602, Israel.
  • Department of Dermatology, Sheba Medical Center, Tel-Hashomer, Ramat-Gan 52621, Israel.
  • Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

ORCID-Profile: Aditya K Gupta, Elizabeth A Cooper

Zitieren

APA

Gupta, A. K., Talukder, M., Cooper, E. A., Magal, L., & Shemer, A. (2025). Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO). Pathogens. https://doi.org/10.3390/pathogens14101049

Vancouver

Gupta AK, Talukder M, Cooper EA, Magal L, Shemer A. Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO). Pathogens. 2025. doi:10.3390/pathogens14101049

BibTeX
@article{Gupta2025,
  author = {Gupta, Aditya K and Talukder, Mesbah and Cooper, Elizabeth A and Magal, Lee and Shemer, Avner},
  title = {Efficacy and Safety of Voriconazole for Difficult-to-Treat Distal Lateral Subungual Onychomycosis (DLSO)},
  journal = {Pathogens},
  year = {2025},
  doi = {10.3390/pathogens14101049}
}
Kostenlos starten →